Status:
RECRUITING
A Non-interventional Registry Study of Fluzoparib in the Treatment of Ovarian Cancer
Lead Sponsor:
Tongji Hospital
Collaborating Sponsors:
First Hospital of China Medical University
Cancer Hospital of Xinjiang Medical University
Conditions:
Ovarian Cancer
Eligibility:
FEMALE
18+ years
Brief Summary
Ovarian cancer is one of the most fatal malignant tumors that threaten women's health. The incidence rate is the third place among the female reproductive system malignant tumors, and the mortality ra...
Detailed Description
Ovarian cancer is one of the most serious malignant tumors that threaten women's health. The incidence rate is third place in the female reproductive system malignant tumors. The mortality rate ranks ...
Eligibility Criteria
Inclusion
- Sign informed consent and voluntarily join the study;
- Epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer diagnosed by histology or cytology;
- ≥ 18 years old;
- The investigator determined that the patient could receive fluzoparib monotherapy or combination therapy;
- For patients with fertility, effective contraceptive methods should be used during the study period and within 90 days after the last administration of fluzoparib
Exclusion
- There is evidence that the patient is a pregnant or lactating woman;
- Participating in any research with intervention measures other than routine clinical practice; 3. The researcher judges other situations that are not suitable for inclusion in the study;
Key Trial Info
Start Date :
January 14 2022
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 31 2032
Estimated Enrollment :
490 Patients enrolled
Trial Details
Trial ID
NCT05206890
Start Date
January 14 2022
End Date
December 31 2032
Last Update
January 26 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology
Wuhan, Hubei, China, 430030